Indivior Pharmaceuticals (INDV) Cash & Current Investments (2021 - 2026)

Indivior Pharmaceuticals' Cash & Current Investments history runs 6 years deep, the most recent figure standing at $175.0 million for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 53.08% year-over-year to $175.0 million; the TTM figure through Mar 2026 stood at $175.0 million (down 53.08% YoY), while the FY2025 annual figure was $195.0 million, down 39.06% from the prior year.
• Cash & Current Investments was $175.0 million for Q1 2026 at Indivior Pharmaceuticals, down from $195.0 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $893.0 million in Q4 2022 to a low of $175.0 million in Q1 2026.
• Historically, Cash & Current Investments has averaged $455.2 million across 5 years, with a median of $409.0 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Cash & Current Investments dropped 18.14% in 2023, then plunged 56.22% in 2024.
• A 5-year view of Cash & Current Investments shows it stood at $893.0 million in 2022, then decreased by 18.14% to $731.0 million in 2023, then slumped by 56.22% to $320.0 million in 2024, then tumbled by 39.06% to $195.0 million in 2025, then dropped by 10.26% to $175.0 million in 2026.
• The last three Cash & Current Investments figures came in at $175.0 million (Q1 2026), $195.0 million (Q4 2025), and $445.0 million (Q3 2025), per Business Quant data.